Analyst firms · Raymond James · BSX

Raymond James BSX price target and rating history

Boston Scientific Corporation (BSX) · Health Care

Raymond James rates Boston Scientific Corporation (BSX) Outperform with a $88 price target, as of its latest action on Mar 30, 2026. It has published 4 rating actions on BSX since July 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a BSX price target in the last 12 months, the median target is $50. Raymond James's $88 is 76% above that.

Current rating
Outperform
Price target
$88
Median target, all firms
$50
Actions on BSX
4

Raymond James price target on BSX

$88$69$4920222023202420252026
Raymond James price target on BSX, each point a stated target, July 2021 to March 2026.

Every Raymond James rating on BSX

How other firms rate BSX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
TD CowenHold$46Oct 30, 2026
OppenheimerPerformOct 29, 2026
BarclaysEqual Weight$48Oct 7, 2026
CitigroupNeutral$50Sep 17, 2026
Argus ResearchHoldJul 31, 2026
Wolfe ResearchPeer PerformMay 29, 2026
Wells FargoEqual Weight$55May 28, 2026
Raymond JamesOutperform$88Mar 30, 2026

Questions about Raymond James and BSX

What is Raymond James's price target for BSX?
Raymond James's latest stated price target for Boston Scientific Corporation (BSX) is $88, from its action on Mar 30, 2026.
What is Raymond James's rating on BSX?
Raymond James rates BSX Outperform, a bullish rating, as of Mar 30, 2026.
When did Raymond James last change its view on BSX?
On Mar 30, 2026, Raymond James downgrades to Outperform from Strong Buy, price target $88.
How does Raymond James's BSX target compare with other analysts?
Across 5 firms with a BSX price target in the last 12 months, the median target is $50. Raymond James's $88 is 76% above that.

More BSX rating histories

All Raymond James ratingsBSX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.